Kas iskelet sistemi yaralanmalarında plateletten zengin plazma tedavisi

ULAŞLI, Alper Murat

Kas iskelet sistemi yaralanmalarında plateletten zengin plazma tedavisi

Alper Murat ULAŞLI (Sungurlu Devlet Hastanesi, Fizik Tedavi ve Rehabilitasyon Kliniği, Çorum, Türkiye)

Afyon Kocatepe Üniversitesi Kocatepe Tıp Dergisi

6 0

Yıl: 2012 Cilt: 13 Sayı: 1 Sayfa Aralığı: 51 - 59 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Kas iskelet sistemi yaralanmalarında plateletten zengin plazma tedavisi

Öz:

Kas iskelet sistemi yaralanmaları uzun dönem şiddetli ağrı ve fiziksel özürlülüğün en sık nedenlerinden biri olup, dünya genelinde yüz milyonlarca kişiyi etkilemektedir. Yara iyileşmesi konusunda yapılan çalışmalar, büyüme faktörlerinin normal doku yapısında ve doku hasarına verilen cevapta kompleks bir regulasyona sahip olduğunu ve hasarlı dokunun iyileşmesinde önemli ve etkin rol üstlendiklerini ortaya çıkarmıştır. Koagulasyon kaskadında önemli rolleri ile bilinen plateletlerin, içerdikleri büyüme faktörleriyle doku tamirinde önemli rol oynadığı anlaşılmıştır. Plateletleri konsantre ederek suprafizyolojik dozlarda büyüme faktörü elde etmek, yara iyileşmesinin hızlandırılması ve daha iyi fonksiyonel düzelme sağlamak, plateletten zengin plazma tedavisinin (PZP) esasını oluşturmaktadır. Lateral epikondilit, aşil tendiniti, rotator tendon lezyonları, ligament ruptürleri, kas yaralanmaları, osteoartrit gibi kas iskelet sistemini ilgilendiren çok çeşitli durumlarda kullanılan PZP ortopedi, fiziksel tıp ve rehabilitasyon, spor hekimliği branşlarının yanında, diş hekimliği, plastik cerrahi, dermatoloji, nöroloji ve oftalmoloji gibi birçok branşın da ilgi alanına girmektedir. Henüz yeni sayılabilecek bu tedavi şeklinin uygulamasında tam bir standardizasyon bulunmamaktadır. Farklı ticari kitler ile farklı ürünler elde edilebilmekte, bu da klinik çalışmalarda tedavi etkinliğinin değerlendirilmesinde sorunlara yol açmaktadır. Bununla birlikte, PZP tedavisinin etkinliğinin değerlendirildiği klinik çalışmalarda umut vadeden sonuçlar elde edilebilmektedir. Yara iyileşmesinde sonucu önceden tahmin edilebilen, hızlı doku tamiri ve fonksiyonel düzelme sağlayabilen tedaviler hedeflenmektedir. Bu bağlamda PZP önemli bir basamak teşkil etmektedir.

Anahtar Kelime:

Konular: Genel ve Dahili Tıp

Platelet rich plasma therapy in musculoskeletal system injuries

Öz:

Musculoskeletal system injuries are the most common cause of long term severe pain and physical disability and affect hundred millions worldwide. Studies concerning wound healing demonstrated that, growth factors have a complex interaction in normal tissue structure and in response to tissue damage, furthermore they play a crucial and effective role in tissue regeneration. Platelets have important role in coagulation cascade, however it has also been proven that, they contain growth factors that play a central role in tissue regeneration. The aim of platelet rich plasma (PRP) therapy is to accelerate wound healing and improve functional restoration by using supraphysiological doses of growth factors in concentrated platelets. PRP therapy, now being used in various musculoskeletal conditions such as lateral epicondilitis, achilles tendinitis, rotator cuff lesions, ligament ruptures, muscle strains, osteoarthritis, is particularly in interest of fields like orthopedics, physical medicine and rehabilitation and sports medicine, but also dentistry, plastic surgery, dermatology, neurology and ophtalmology. There is lack of standardization of this new therapy modality. There are various kind of commercial kits which may produce different PRP s causing difficulties in evaluating the results of clinical studies. However there are promising results in clinical studies assesing the effect of PRP s. The target of new therapies is to obtain predictable, rapid tissue regeneration and functional improvement. In this context, PRP serves as an important step.

Anahtar Kelime:

Konular: Genel ve Dahili Tıp

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1.Woolf AD, Pfleyer B. Burden of major musculoskeletal conditions. Bull World Health Organ. 2003;81:646656.
2.Buckwalter JA, Mankin HJ. Articular cartilage. Part II: Degeneration and osteoarthrosis, repair, regeneration, and tranplantation. J Bone Joint Surg. 1998;79:A:612632.
3.Parkkari J, Pasanen K, Mattila VM, Kannus P, Rimpela ̈ A. The risk for a cruciate ligament injury of the knee in adolescents and young adults: a population-based cohort study of 46 500 people with a 9 year follow-up. Br J Sports Med. 2008;42:422 426.
4.Peers KH, Lysens RJ. Patellar tendinopathy in athletes: current diagnostic and therapeutic recommendations. Sports Med. 2005;35:7187.
5.Kasemkijwattana C, Menetrey J, Bosch P, Somogyi G, Moreland MS, Fu FH, Buranapanitkit B, Watkins SS, Huard J. Use of growth factors to improve muscle healing after strain injury. Clin Orthop Relat Res. 2000;370:272285.
6.Molloy T, Wang Y, Murrell G. The roles of growth factors in tendon and ligament healing. Sports Med. 2003;33:381394.
7.Nagumo A, Yasuda K, Numazaki H, et al. Effects of separate application of three growth factors (TGF- beta1, EGF, and PDGF-BB) on mechanical properties of the in situ frozenthawed anterior cruciate ligament. Clin Biomech. 2005;20:283290.
8.Pujol JP, Chadjichristos C, Legendre F, et al. Interleukin- 1 and transforming growth factor-beta 1 as crucial factors in osteoarthritic cartilage metabolism. Connect Tissue Res 2008;49:293297.
9.Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA. Platelet-rich plasma: from basic science to clinical applications. Am J Sports Med 2009; 37:22592272.
10.Wroblewski AP, Melia HJ, Wright VJ. Application of platelet-rich plasma to enhance tissue repair. Oper Tech Orthop. 2010; 20:98105.
11.Anitua E, Sanchez M, Nurden AT, Nurden M, Orive G, Andia I. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol. 2006;24(5):227-234.
12.Anitua E, Sanchez M, Orive G, Andia I. The potential impact of the preparations rich in growth factors (PRGF)in different medical fields.Biomaterials. 2007;28:2551-4560.
13.Marx R. Platelet-function: assays and events introduction. Suppl Thromb Haemost 1978; 63:6580.
14.Everts PA, Knape JT, Weibrich G, et al. Platelet rich plasma and platelet gel: a review. J Extra Corpor Technol. 2006; 38:174187.
15.Drezner JA. Practical management: Hamstring muscle injuries. Clin J Sport Med 2003;13:4852.
16.Chan YS, Li Y, Foster W, Fu FH, Huard J. The use of suramin, an antifibrotic agent, to improve muscle recovery after strain injury. Am J Sports Med. 2005;33:4351.
17.Tidball JG. Inflammatory processes in muscle injury and repair. Am J Physiol Regul Integr Comp Physiol. 2005;288:R345353.
18.Lyras DN, Kazakos K, Verettas D, et al. The influence of platelet-rich plasma on angiogenesis during the early phase of tendon healing. Foot Ankle Int 2009; 30:11011106.
19.Schnabel LV, Mohammed HO, Miller BJ, et al. Platelet rich plasma (PRP) enhances anabolic gene expression patterns in flexor digitorum superficialis tendons. J Orthop Res. 2007;25:230240.
20.Smith SE, Roukis TS. Bone and wound healing augmentation with platelet-rich plasma. Clin Podiatr Med Surg 2009;26:559588.
21.Mast BA. Healing in other tissues. Surg Clin North Am. 1997; 77(3):529-547 .
22.Nurden AT, Nurden P, Sanchez M, Andia I, Anitua E. Platelets and wound healind. Frontiers in Bioscience. 2008;13:3532-3548.
23.Heldin CH, Westermark B. Platelet-derived growth factors: A family of isoforms that bind to two distinct receptors. Br Med Bull. 1989;45:453464.
24.Ross R, Ralnes EW, Bowen-Pope DF. The biology of platelet-derived growth factor. Cell. 1986;46:155 169.
25.Senior RM, Griffin GL, Huang JS, Walz DA, Deuel TF. Chemotactic activity of platelet alpha granule proteins for fibroblasts. J Cell Biol. 1983;96:382385.
26.Sciore P, Boykiw R, Hart DA. Semi-quantitive reverse transcriptase polymerase chain reaction analysis of mRNA for growth factors and growth factor receptors from normal and healing rabbit medial collateral ligament tissue. J Orthop Res. 1998; 16: 429-437.
27.Jones JI, Clemmons D. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16(1):3-34.
28.Abrahamsson SO. Similar effects of recombinant human insulin-like growth factor-I and II on cellular activities in flexor tendons of young rabbits: experimental studies in vitro. J Orthop Res 1997;15 (2): 256-262.
29.Tsuzaki M, Brigman B, Yamamoto J K, et al. Insulin- like growth factor-I is expressed by avian flexor tendon cells. J Orthop Res. 2000; 18(4):546-556.
30.Sporn MB, Roberts AB, Wakefield LM, et al. Transforming growth factor beta: Biological function and chemical structure. Science. 1986;233:532534.
31.Roberts AB, Anzano MA, Wakefield LM, et al. Type beta transforming growth factor: A bifunctional regulator of cellular growth. Proc Natl Acad Sci USA. 1985;82:119123.
32.Molloy T, Wang Y, Murrel G A.C. The roles of growth factors in tendon and ligament healing. Sports Med. 2003;33(5)381-394.
33.Borrione P, Gianfrancesco A, Pereira MT, Pigozzi F. Platelet rich plasma in muscle healing. Am J PHYS Med Rehabil. 2010;89:854-861.
34.Jackson JR, Minton J, Ho ML, et al. Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1beta. J Rheumatol. 1997;24(7):1253-1259.
35.Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Kocatepe Tıp Dergisi, Cilt 13 No:1,Ocak 2012 Oral Med Oral Pathol Oral Radiol Endod. 1998; 85:638646.
36.Griffin XL, Smith CM, Costa ML. The clinical use of platelet-rich plasma in the promotion of bone healing: a systematic review. Injury 2009;40:158-162.
37.Mei-Dan O, Lippi G, Sanchez M, Andia I, Matfulli N. Autologous platelet-rich plasma: arevolution in soft tissue sports injury management? Phys Sportsmed 2010;38:127-135.
38.Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent 2001;10:225228.
39.Weibrich G, Kleis WK, Hafner G, Hitzler WE. Growth factor levels in platelet-rich plasma and correlations with donor age, sex, and platelet count. J Craniomaxillofac Surg 2002;30:97-102.
40.Lee KS,Wilson JJ, Rabago DP, Baer GS, Jacobson JA, Borrero CG. Musculoskeletal applications of platelet- rich plasma: Fad or future? AJR 2011;196:628-636.
41.Sampson S, Gerhardt M, Mandelbaum B. Platelet rich plasma injection grafts for musculoskeletal injuries: a review Curr Rev Musculoskelet Med. 2008; 1:165-174.
42. de Vos RJ, Weir A, van Schie HT, et al. Platelet-rich plasma injection for chronic Achilles tendinopathy: a randomized controlled trial. JAMA. 2010;303:144-9.
43.Chen CH, Cao Y, Wu YF, Bais AJ, Gao JS, Tang JB. Tendon healing in vivo: gene expression and production of multiple growth factors in early tendon healing period. J Hand Surg Am. 2008;33:18341842.
44.Kobayashi M, Itoi E, Minagawa H, et al. Expression of growth factors in the early phase of supraspinatus tendon healing in rabbits. J Shoulder Elbow Surg. 2006;15:371377.
45.Aspenberg P. Stimulation of tendon repair: mechanical loading, GDFs and platelets. A mini- review. Int Orthop 2007:31:783789.
46.Klein MB, Yalamanchi N, Pham H, Longaker MT, Chang J. Flexor tendon healing in vitro: effects of TGF- beta on tendon cell collagen production. J Hand Surg Am. 2002:27:615620.
47.Sanchez M, Azofra J, Anitua E, et al. Plasma rich in growth factors to treat an articular cartilage avulsion: a case report. Med Sci Sports Exerc. 2003;35:1648 1652.
48.Mishra A, Pavelko T. Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. Am J Sports Med. 2006;34:17741778.
49.Peerbooms JC, Sluimer J, Bruijn DJ, Gosens T. Positive effect of an autologous platelet concentrate in lateral epicondylitis in a double-blind randomized controlled trial: platelet-rich plasma versus corticosteroid injection with a 1-year follow-up. Am J Sports Med. 2010;38:255262.
50.Filardo G, Kon E, Della Villa S, Vincentelli F, Fornasari PM, Marcacci M. Use of platelet rich plasma fort he treatment of refractory jumpers knee. Int Orthop. 2009;34(6):909-915.
51.Everts PA, Devilee RJ, Mahoney CB, Exagenous application of platelet-leukocyte gel during open subacromial decompressioncontributes to patient outcome. A prospective randomized double-blind study. European Surg Repair. 2008;40(2);203-210.
52.Sánchez M, Anitua E, Azofra J, Prado R, Muruzabal F, Andia I. Ligamentization of tendon grafts treated with an endogenous preparation rich in growth factors: gross morphology and histology. Arthroscopy. 2010;26(4):470-80.
53.Radice F, Yanez R, Gutierrez V, Rosales J, Pinedo M, Coda S. Comparison of magnetic resonance imaging findings in anterior cruciate ligament grafts with and withour autologous platelet derived growth factors. Arthroscopy. 2010;26(1):50-57.
54.Barrett SL, Erredge SE. Growth factors for chronic plantar fasciitis. Podiatry Today. 2004; 17:3742.
55.Kon E, Filardo G,Martino A,Marcacci M. Platelet- rich plasma (PRP) to treat sports injuries: evidence to support its use. Knee Surg Sports Traumatol Arthrosc. 2011;19:516-527.
56.Sanchez M, Anitua E, Azofra J, Aguirre JJ, Andia I. Intraarticular injection of an autologous preparation rich in growth factors for the treatment of knee OA: a retrospective cohort study. Clin Exp Rheumatol 2008;(26):910913.
57.Kon E, Buda R, Filardo G, Di et al. Platelet-rich plasma: intra-articular knee injections produced favorable results on degenerative cartilage lesions. Knee Surg Sports Traumatol Arthrosc 2010;18:472 479.

APA	ULAŞLI A (2012). Kas iskelet sistemi yaralanmalarında plateletten zengin plazma tedavisi. , 51 - 59.
Chicago	ULAŞLI Alper Murat Kas iskelet sistemi yaralanmalarında plateletten zengin plazma tedavisi. (2012): 51 - 59.
MLA	ULAŞLI Alper Murat Kas iskelet sistemi yaralanmalarında plateletten zengin plazma tedavisi. , 2012, ss.51 - 59.
AMA	ULAŞLI A Kas iskelet sistemi yaralanmalarında plateletten zengin plazma tedavisi. . 2012; 51 - 59.
Vancouver	ULAŞLI A Kas iskelet sistemi yaralanmalarında plateletten zengin plazma tedavisi. . 2012; 51 - 59.
IEEE	ULAŞLI A "Kas iskelet sistemi yaralanmalarında plateletten zengin plazma tedavisi." , ss.51 - 59, 2012.
ISNAD	ULAŞLI, Alper Murat. "Kas iskelet sistemi yaralanmalarında plateletten zengin plazma tedavisi". (2012), 51-59.

APA	ULAŞLI A (2012). Kas iskelet sistemi yaralanmalarında plateletten zengin plazma tedavisi. Afyon Kocatepe Üniversitesi Kocatepe Tıp Dergisi, 13(1), 51 - 59.
Chicago	ULAŞLI Alper Murat Kas iskelet sistemi yaralanmalarında plateletten zengin plazma tedavisi. Afyon Kocatepe Üniversitesi Kocatepe Tıp Dergisi 13, no.1 (2012): 51 - 59.
MLA	ULAŞLI Alper Murat Kas iskelet sistemi yaralanmalarında plateletten zengin plazma tedavisi. Afyon Kocatepe Üniversitesi Kocatepe Tıp Dergisi, vol.13, no.1, 2012, ss.51 - 59.
AMA	ULAŞLI A Kas iskelet sistemi yaralanmalarında plateletten zengin plazma tedavisi. Afyon Kocatepe Üniversitesi Kocatepe Tıp Dergisi. 2012; 13(1): 51 - 59.
Vancouver	ULAŞLI A Kas iskelet sistemi yaralanmalarında plateletten zengin plazma tedavisi. Afyon Kocatepe Üniversitesi Kocatepe Tıp Dergisi. 2012; 13(1): 51 - 59.
IEEE	ULAŞLI A "Kas iskelet sistemi yaralanmalarında plateletten zengin plazma tedavisi." Afyon Kocatepe Üniversitesi Kocatepe Tıp Dergisi, 13, ss.51 - 59, 2012.
ISNAD	ULAŞLI, Alper Murat. "Kas iskelet sistemi yaralanmalarında plateletten zengin plazma tedavisi". Afyon Kocatepe Üniversitesi Kocatepe Tıp Dergisi 13/1 (2012), 51-59.